Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

Published:2006-12 Issue:12 Volume:3 Page:668-681
ISSN:1743-4254
Container-title:Nature Clinical Practice Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Muranski Pawel,Boni Andrea,Wrzesinski Claudia,Citrin Deborah E,Rosenberg Steven A,Childs Richard,Restifo Nicholas P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,General Medicine

Link

http://www.nature.com/articles/ncponc0666.pdf

Reference116 articles.

1. Rosenberg SA et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

2. Rosenberg SA et al. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907–913

3. Dutcher JP et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7: 477–485

4. Legha SS et al. (1996) Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 77: 89–96

5. Rosenberg SA et al. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909–915

Cited by 304 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Altered cancer metabolism and implications for next-generation CAR T-cell therapies;Pharmacology & Therapeutics;2024-07

2. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers;Communications Medicine;2024-06-13

3. Programmable cancer treatments: Engineering biology approaches for living cures;Engineering Biology;2024-05-31

4. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma;Cytotherapy;2024-05

5. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy;International Immunopharmacology;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3